Joana Cardigos

Dr. Joana Cardigos


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FBFilipe Barcelos
Filipe Barcelos
CMCatarina Gregório Martins
Catarina Gregório Martins
RMRicardo Monteiro
Ricardo Monteiro
JCJoana Cardigos
Joana Cardigos
TPTiziano Prussiani
Tiziano Prussiani
LBLuís Miguel Borrego
Luís Miguel Borrego
Sjögren's syndrome (SjS) is characterized by lymphocytic infiltration of exocrine glands, i.e. autoimmune epithelitis. Lymphocytes are central in SjS pathogenesis, with B-cell hyperactivity mediated by T-cells. B-cells are main targets of Epstein-Barr virus (EBV) infection, a frequently-suggested trigger for SjS. We aimed to evaluate how the EBV infection modulates B and T-cell subsets in SjS, including as controls Rheumatoid arthritis patients (RA) and healthy participants (HC). SjS patients presented decreased CXCR5+T-cells, although IL21-secreting Tfh and Tfc cells were increased. Tfc were positively correlated with ESSDAI scores, suggesting their relevant role in SjS pathogenesis. As previously described, SjS patients showed expanded circulating naïve B-cell compartments. SjS patients had a higher incidence of EBV-EA-D-IgG+ antibodies, characteristic of recent EBV-infection/reactivation. SjS patients with past infection or recent infection/reactivation showed increased CXCR3+Th1 and CXCR3+Tfh1 cells compared to those without active infection. SjS patients with a recent infection/reactivation profile presented increased transitional B-cells compared to patients with past infection and increased plasmablasts, compared to those without infection. Our results suggest EBV-infection contributes to B and T-cell differentiation towards the effector phenotypes typical of SjS. Local lymphocyte activation at ectopic germinal centres, mediated by Tfh and Tfc, can be EBV-driven, perpetuating autoimmune epithelitis, which leads to gland destruction in SjS.

6 April 2018 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
FBFilipe Barcelos
Filipe Barcelos
CMCatarina Gregório Martins
Catarina Gregório Martins
APAna Papoila
Ana Papoila
CBCarlos Brás-Geraldes
Carlos Brás-Geraldes
JCJoana Cardigos
Joana Cardigos
LBLuís Miguel Borrego
Luís Miguel Borrego

14 January 2021 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
FBFilipe Barcelos
Filipe Barcelos
CMCatarina Gregório Martins
Catarina Gregório Martins
NMNathalie Madeira
Nathalie Madeira
MÂMiguel Ângelo Simão Ângelo-Dias
Miguel Ângelo Simão Ângelo-Dias
JCJoana Cardigos
Joana Cardigos
LBLuís Miguel Borrego
Luís Miguel Borrego

8 March 2021 in Acta Ophthalmologica
Verified
Journal Article
Closed access
PDF file
FBFilipe Barcelos
Filipe Barcelos
DHDiogo Hipólito‐Fernandes
Diogo Hipólito‐Fernandes
CMCatarina Gregório Martins
Catarina Gregório Martins
MÂMiguel Ângelo Simão Ângelo-Dias
Miguel Ângelo Simão Ângelo-Dias
JCJoana Cardigos
Joana Cardigos
LBLuís Miguel Borrego
Luís Miguel Borrego

1 April 2025 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
BCBruna Cunha
Bruna Cunha
PGPedro Gil
Pedro Gil
ELEdgar Lopes
Edgar Lopes
MLMaria Elisa Luis
Maria Elisa Luis
MRMaria Reina
Maria Reina
JCJoana Cardigos
Joana Cardigos
Purpose: To compare the short-term efficacy and safety of the PRESERFLO™ MicroShunt (PF) versus Non-Penetrating Deep Sclerectomy (NPDS) with Esnoper®. Methods: Retrospective comparative cohort study at a tertiary hospital including 79 eyes from 79 patients submitted to surgery (32 PF implantation, Group 1 and 47 NPDS, Group 2) between January 2022 and August 2023, with one year follow-up. Outcome measures included intraocular pressure (IOP), complications, surgical duration, postoperative major and minor interventions. Surgical failure was defined as IOP> 21 mmHg or < 20% reduction from baseline, IOP< 5 mmHg, major postoperative intervention, or loss of light perception. Conversely, success was defined as the absence of these failure criteria: complete success without glaucoma medications, and qualified success with. Results: Baseline characteristics, including age, sex, IOP, number of IOP-lowering medications, and visual field defects, were comparable between groups (p> 0.05). After one year, IOP decreased significantly in both groups (PF: 20.13± 6.20 to 15.00± 3.15 mmHg; NPDS: 19.57± 5.73 to 13.30± 3.59 mmHg, both p< 0.001). Complete success rates were 28.1% for PF and 40.4% for NPDS (p=0.189), while surgical failure was significantly higher in the PF group (65.6% vs 38.3%, p=0.015). Major reinterventions were more frequent with PF (10 vs 3, p=0.005), partly due to encapsulated blebs, while NPDS required more minor interventions (2 vs 17, p=0.002). Complication rates were similar (31.3% vs 14.9%, p=0.073), but surgical duration was shorter in the PF group (60.03± 17.95 min vs 69.91± 15.23 min, p=0.008). Conclusion: PF and NPDS share comparable safety profiles. Although PF surgery is faster, it is associated with a higher rate of major postoperative interventions and failure. NPDS, while requiring more minor interventions, such as goniopuncture and needling, rarely demands major re-interventions. NPDS is known for its meticulous and technically challenging technique, but once mastered, it can result in fewer invasive re-interventions and improved efficacy.